Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc (CRVS) Implied Volatility Current
CRVS's 30 day implied volatility is 93.86%, with an IV Rank of 63.49%. This is an average IV Rank versus the past year, meaning Corvus Pharmaceuticals Inc options are fairly priced and currently offer no clear edge to buyers or sellers. CRVS's 30 day historical volatility sits at 67.07%, which means implied volatility is running 26.79 points above historical volatility, as of Nov 16, 2026.
Read more
Tracking CRVS implied volatility helps you spot when Corvus Pharmaceuticals Inc options are historically cheap or expensive, and where the best trades are hiding. When CRVS IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor CRVS implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking CRVS IV rank helps you see whether CRVS's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.
Implied Volatility
IV is slightly elevated. Premiums are richer, leaning toward sellers.
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →